Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ:BIOR)

0.5597 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Biora Therapeutics Successfully Completes Restructuring Process
Emerges as a privately held company, with long-term financing to accelerate development of the BioJet™ platform 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Biora Therapeutics (BIOR) Stock Is Down 45%
Biora Therapeutics shares are trading lower by 45% during Tuesday's session. The company announced that it will be delisted from Nasdaq. 
Via Benzinga
Biora Therapeutics's Earnings Outlook
Via Benzinga
Dow Falls 150 Points; Oracle Posts Downbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Expanded collaborations to support rapid testing in advanced animal models in Q4 2024 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Achieves ISO 13485 Certification
Underscoring the company’s commitment to quality and excellence 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Positive Nasdaq Listing Decision
Company granted extension to regain compliance with Nasdaq listing requirements 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024
BIOR stock results show that Biora Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Funding Agreement with Existing Investors
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.